Matt Abernethy sold $299K of Neurocrine Biosciences (NBIX)

Executed Feb 13 2025, disclosed Feb 14 2025, 1 day later.

Value, as filed

$299K

2,558 sh across 2 lots

Executed

Feb 13 2025

the trade date, as filed

Disclosed

Feb 14 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

MA Matt Abernethy Chief Financial Officer profile →

Matt Abernethy (Chief Financial Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $363K of NBIX (2,311 sh × $157.20, as filed), executed Sep 14.

The name

NBIX Neurocrine Biosciences, Inc. NBIX · Healthcare · 59 filings in 24 months ticker →

Healthcare · Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunolog…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Matt Abernethy in NBIX

NBIXSALE Neurocrine Biosciences, Inc. $363K
2,311 sh × $157.20
Exec Sep 14
Filed Sep 15 · 5:02 PM ET NBIXSALE Neurocrine Biosciences, Inc. $116K
980 sh × $118.27
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $196K
1,283 sh × $152.87
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET